A meta-analysis suggests that high doses of psilocybin may alleviate depressive symptoms similarly to the SSRI drug escitalopram. While the effect size was small, psilocybin outperformed placebo in clinical trials, though study design flaws could have led to overestimated results. The findings indicate that psilocybin, particularly in high doses, may offer a new avenue for treating depression, comparable to existing antidepressants.

Researchers warn that mushroom gummies sold to boost brain function may contain illegal hallucinogens and other harmful ingredients, after five people, including a 3-year-old, fell ill. Testing revealed that three out of five brands contained psilocybin or psilocin, Schedule I drugs, which were not listed on the labels. This poses a public health threat, as consumers are unaware of what they are ingesting.

A new study reveals that psilocybin, the active compound in magic mushrooms, temporarily disrupts brain networks involved in introspective thinking, like daydreaming and memory. These changes persist for weeks, potentially making the brain more flexible and improving mental health. The findings could pave the way for psilocybin-based therapies for depression and PTSD. The research underscores the importance of using these drugs under medical supervision.